Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.

Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [JS: Speaker’s honorarium: ‘Astellas, Bayer’. ML: Advisory (institution): AstraZeneca, GlaxoSmithKline, Illumina, Janssen-Cilag, Lilly, MSD, Medtalks. CvH: Advisory (institution): Bayer, Bristol-Myers Squibb, Ipsen, MSD, Regeneron, and Philips Molecular Pathway Diagnostics. Research grant (institution): Astra Zeneca, Bristol-Myers Squibb, MSD, Merck, Ipsen, Novartis, and Sanofi.JW, TdB, GV, WvB, MU, AvEvG, CD: Nothing to declare.].